Funding newsPublished July 28, 2026

Neurimmune AG Raises $125.

Recently funded · $125.0M UnknownManufacturingCHView source

Get the full Neurimmune AG company profile

Access contacts, investors, buying signals & more

The pursuit of new treatments for neurodegenerative diseases has received a substantial injection of capital, with clinical-stage biopharmaceutical company Neurimmune AG announcing it has raised $125.0M. The funding will accelerate its development of next-generation antibody therapeutics.

Neurimmune is pioneering amyloid depletion as a novel therapeutic mechanism. This approach targets CNS and related protein aggregation diseases, including Alzheimer’s disease, amyotrophic lateral sclerosis, and ATTR cardiomyopathy.

Other Switzerland companies recently funded

View all

SurgExplore
SurgExplore is an AI-powered surgical intelligence platform that transforms recorded surgery video and clinical data into surgeon-specific and patient-specific training, pre-operative planning, and automated post-operative reporting. We are a spin-off from the University of Bern's AIMI Lab and ARTORG Center, built on more than seven years of peer-reviewed research in surgical AI and the development of the largest annotated surgical datasets in the world. Across surgical specialties, healthcare systems struggle to scale reliable, high-quality care. Training is resource-intensive and depends on prolonged expert supervision. Planning follows protocols rather than patient data. Documentation is manual and often incomplete. Preventable complications go undetected until they become costly, billing is delayed by fragmented records, and follow-up is generic rather than tailored to the individual patient. The data needed to address this already exists in every operating room, largely unstructured and unused. SurgExplore turns that data into actionable clinical intelligence: optimizing surgical training, supporting risk-aware pre-operative planning, reducing preventable complications, personalizing patient follow-up, and streamlining documentation and billing in ways that lower hospital costs and improve patient outcomes. Our platform integrates with the surgical equipment hospitals already own, requiring no new capital investment or changes to existing workflows. We work with leading hospitals and surgical training centers across Switzerland, Europe, and internationally, with pilot deployments beginning in 2026. Our mission is to transform surgical video and clinical data into intelligence that accelerates training, sharpens pre-operative planning, and streamlines post-operative reporting, reducing costs, preventing complications, and improving patient outcomes across surgical care.

Biggest recent Biotechnology rounds

Largest funding rounds in Biotechnology on Signalbase right now.

#	Company	Round	Amount	Date
1	Shockwave Medical United States	Unknown	$13.1B	1y ago
2	NeuroEM Therapeutics United States	Unknown

Other recent Unknown rounds

Companies that recently closed a Unknown round.

#	Company	Round	Amount	Date
1	Zenith Energy Canada	Unknown	$2.8M	today
2	COR United States	Unknown	$30.0M	today
3

Neurimmune AG Raises $125.

Other Switzerland companies recently funded

Biggest recent Biotechnology rounds

Other recent Unknown rounds

Unlock Neurimmune AG's full profile

Investors

Similar recently funded companies